First-in-kind real-time pharmacokinetic data in a mouse tumor model confirmed WTX-124 selective activation in tumors, sparing healthy tissue WATERTOWN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- ...
Participation in the Jefferies Global Healthcare Conference highlights Werewolf Therapeutics' commitment to engagement with the investment community and showcases its innovative approach to cancer ...